|Bid||39.34 x 1000|
|Ask||39.39 x 1300|
|Day's Range||38.00 - 40.09|
|52 Week Range||10.41 - 40.09|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||82.18|
|Earnings Date||Dec 9, 2019 - Dec 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.14|
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
Arrowhead Pharma stock flirted with a breakout Friday after the biotech company said it's experimenting with silencing multiple genes as well as moving into diseases outside the liver.
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Christopher Anzalone, president and CEO of Arrowhead Pharmaceuticals , the development-stage biotech focusing on gene therapy. Anzalone explained that Arrowhead is pioneering gene therapies developed around the concept of RNA interference, which acts to silence, or turn off, certain genes that are known to cause disease. Arrowhead currently has big name partnerships with Johnson & Johnson and Amgen to help them develop and commercialize various drugs based off of the company's technology.
Arrowhead Pharmaceuticals, Inc. is hosting a Research & Development Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform platform.
Medical stocks dominate today’s top charts to watch. AbbVie Inc. (ABBV) climbed $1.72 to $73.85 on 6.2 million shares traded Thursday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped $1 to $29.92 on 883,800 shares traded Thursday.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform from 8:30 a.m. to 11:30 a.m. EDT on October 18, 2019, in New York City. The meeting will feature a presentation by Ira Goldberg, M.D. (NYU Langone Medical Center), who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia.
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to participate in the following upcoming events:
By Brian Marckx, CFA NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Pipeline Highlights: APOC3/ANG3 Topline Data, Orphan Desig. JNJ-3989 in Ph2b, Cohort 12 Data Upcoming. And More … Arrowhead (NASDAQ:ARWR) continues to make rapid progress across most of their pipeline. There has been no shortage of positive product development related events as
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on September 13, 2019, the Compensation Committee of the Board of Directors approved "inducement" grants to 17 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 211,000 shares of common stock and 20,875 restricted stock units. The strike price of the options is set at an exercise price per share of $29.95, the last reported closing price of the Company's common stock on September 13, 2019, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of nine new employees, anticipated to be within two months of the date of the approval.
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will...
Arrowhead Pharmaceuticals Inc. today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE. The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III and ARO-ANG3 reduced plasma angiopoietin like protein 3 , and both candidates reduced triglycerides without ...
Arrowhead Pharmaceuticals stock flirted with a breakout Thursday after earning a $25 million milestone payment as its hepatitis B treatment with Johnson & Johnson begins midstage testing.
The company announced its treatment for hepatitis B is being investigated in Janssen Pharmaceuticals’ Phase 2b study. The stock has been in a beautiful up-channel this year, doubling since the start of May, and the rising channel top points to $39 next. Luckin Coffee Inc. (LK) popped $1.55, or 8%, to $21.03 on 3.6 million shares on no news reported by the company.
- U.S. Patent and Trademark Office publishes Arrowhead's latest patent application on αvβ6 integrin ligands. - αvβ6 integrin ligands enable high affinity extrahepatic delivery of RNAi trigger sequences to multiple tissues. - Arrowhead cornering the market on its patent pending extrahepatic compositions for targeting αvβ6 integrin ligands. - The company that is able to move […]
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful...
BioBoyScout, founded by Intellectual Property attorney Robert Toczycki, JD, MBA, has developed online biotech valuation calculators that enable small investors to compete with the big Wall Street institutions. The calculators can be modified to a user’s liking and apply the same financial valuation models used by most Wall Street analysts. BioBoyScout began developing its models […]